Optimise viewing for

Toggle between patient and health professional views. The patient version is simplified to help people easily find suitable trials, while the professional view provides full detail.

RecruitingLast updated: 16 May 2025

BLOCK PCNSL (NHL32): This phase II study is trying to determine if standard chemotherapy induction therapy followed by immunotherapy (pembrolizumab) will be effective in maintaining life expectancy with minimal side effects for people with primary central nervous system lymphomaAn ALLG Phase II study of pembrolizumab checkpoint blockade following chemoimmunotherapy for primary central nervous system lymphoma

Trial purpose

Medical clipboardCancer treatment

Tumor type

Blood Cancers Haematological

Age

People18+

Trial acronym

BLOCK PCNSL (NHL32)

Clinical summary

Summary

All participants in this trial will receive chemotherapy induction therapy (CIT) of either A) Rituximab, Methotrexate, Procarbazine & Vincristine (R-MPV) Cytarabine (Ara-C); or B) Cytarabine, Thiopeta & Rituximab (MATRix). The CIT given is at the discretion of the participant's clinician and is not assessed as part of this study. Once the induction treatment is complete, participants will receive Pembrolizumab immunotherapy (200mg via intravenous infusion) commencing 4-6 weeks after last CIT exposure, and administered every 3 weeks for 35 cycles/2 years.

Conditions

This trial is treating people with primary central nervous system lymphoma

Eligibility

Inclusion

 

Treatment-naïve new diagnosis of PCNSL (DLBCL)
Age = greater than or equal to 18 years
ECOG = less than or equal to 3
Considered appropriate for induction CIT as per investigator
No standard contraindication to immune checkpoint inhibition

Exclusion

Active autoimmune disease
Unfit for induction CIT (prohibitive organ dysfunction)
Non-B-cell lymphoma subtype
Systemic involvement with aggressive lymphoma

Inclusion

  • You have been diagnosed with cancer, but have not received any treatment.

Exclusion

  • You have certain types of non-cancer medical conditions.
Message

Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.

Participating hospitals

Recruiting hospitals

+ Show non-recruiting hospitals

No longer recruiting (closed or complete) hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

More information

Trial Identifiers

Information on this page is partially produced from ANZCTR *. View further details about this trial on the registry via the links below:

Trial sponsor

Merck,Australasian Leukaemia and Lymphoma Group (ALLG)

Scientific Title

An ALLG Phase II study of pembrolizumab checkpoint blockade following chemoimmunotherapy for primary central nervous system lymphoma

Get Support

Cancer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Cancer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Know more about Cancer Connect

Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Get support

Multilingual information

Learn more about clinical trials through this collection of resources in languages other than English.

View information